Business
Harmony Biosciences Reports Strong 2024 Revenues, Provides 2025 Revenue Guidance and Highlights Key Pipeline Catalysts
WAKIX® (pitolisant) Preliminary Net Revenue of ~$201 Million for Fourth Quarter and ~$714 Million for Full Year 2024; Representing Growth of ~23% in
About this update from Harmony Biosciences Holdings, Inc.
[{"type":"text","content":"\nWAKIX® (pitolisant) Preliminary Net Revenue of ~$201 Million for Fourth Quarter and ~$714 Million for Full Year 2024; Representing Growth of ~23% in Year-Five of Launch\n\n\n2025 WAKIX Net Revenue Guidance Between $820 - $860 Million; On Track to a Potential $1 Billion+ Opportunity\n\n\nValue-Creating Catalysts Anticipated Every Quarter in 2025:\n\n\nQ1 – FDA Decision on File Acceptance of Pitolisant sNDA for Idiopathic Hypersomnia; Potential Approval in 2025\nQ2 – Orexin/BP1.15205 Data Presentation at SLEEP 2025 Conference\nQ3 – Pivotal Phase 3 Topline Data for ZYN002 in Fragile X Syndrome\nQ4 – Initiation of Pitolisant-HD Pivotal Phase 3 Trial in Narcolepsy\n\n\nRobust, Catalyst-Rich Pipeline Includes Up to Six Phase 3 Clinical Programs by Year End 2025\n\n\n PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--\nHarmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced strong preliminary, unaudited net product revenues for Q4 and full year 2024 of $201 million and $714 million, respectively. Building on this performance, the company is well positioned for a catalyst-rich 2025, with value-creating milestones anticipated every quarter. Harmony will be highlighting its catalysts for 2025 and other key milestones during its presentation at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, at 11:15 a.m. PT / 2:15 p.m. ET.\n\n\n“2025 is a pivotal year for Harmony Biosciences, as we focus on unlocking the full potential of our catalyst-rich neuroscience pipeline,” said Jeffrey M. Dayno, M.D., President and Chief Executive Officer of Harmony Biosciences. “Building upon our foundation of strong and continued revenue growth for WAKIX, our multi-franchise pipeline has come into focus with value-creating catalysts expected each and every quarter this year. We are entering 2025 with strong momentum and a clear path toward long-term growth, building a company with the potential to deliver over $3 billion in net revenue going forward.\"\n\n\nFourth Quarter and Full Year 2024 Net Product Revenue for WAKIX (Preliminary and Unaudited)\n\n\n\nPreliminary, unaudited net product revenue for the quarter ended December 31, 2024, was approximately $201 million, compared to $168.4 million for the same period in 2023\n\n\n\nPreliminary, unaudited net product revenue for the full year ended December 31, 2024, was approximat...